Lower dosage strength imiquimod formulations and short...

Details Lower dosage strength imiquimod formulations and short... Lower dosage strength imiquimod formulations and short...

A - Human Necessities

61

K

A61K 31/4745 (2006.01) A61K 47/12 (2006.01) A61P 17/12 (2006.01)

Patent

CA 2709732

Pharmaceutical formulations and methods for the topical or transdermal delivery of 1-isobutyl-1H-imidazo[4,5-c]-quinolin-4-amine or 1-(2- methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine, i.e., imiquimod, to treat actinic keratosis with short durations of therapy, than currently prescribed for the commercially available Aldara ® 5% imiquimod cream, as now approved by the U.S. Food & Drug Administration ("FDA"), are disclosed and described. More specifically, lower dosage strength imiquimod formulations to deliver an efficacious dose of imiquimod for treating actinic keratosis with an acceptable safety profile and dosing regimens that are short and more convenient for patient use than the dosing regimen currently approved by the U.S. Food & Drug Administration ("FDA") for Aldara ® 5% imiquimod cream to treat actinic keratosis are also disclosed and described.

Affiliated with

Also associated with

Rating

Lower dosage strength imiquimod formulations and short... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Lower dosage strength imiquimod formulations and short..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Lower dosage strength imiquimod formulations and short... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-1539893